Bioventus Inc. (BVS)

Market Cap	697.47M
Revenue (ttm)	555.06M
Net Income (ttm)	-39.48M
Shares Out	65.37M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	20.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	506,407
Open	10.27
Previous Close	10.52
Day's Range	10.27 - 10.80
52-Week Range	3.90 - 14.38
Beta	0.79
Analysts	Strong Buy
Price Target	15.00 (+40.58%)
Earnings Date	Nov 5, 2024

About BVS

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that in...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 2021
• Employees: 970
• Stock Exchange: NASDAQ
• Ticker Symbol: BVS
• Website: https://www.bioventus.com

Financial Performance

In 2023, Bioventus's revenue was $512.35 million, an increase of 0.04% compared to the previous year's $512.12 million. Losses were -$156.23 million, -1.56% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 40.58% from the latest price.

Price Target

$15.0

(40.58% upside)

Analyst Consensus: Strong Buy